HARDMAN & CO RESEARCH Hardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
Transparency directive : regulatory news
|
Hardman & Co Research
Hardman & Co Research on Advanced Oncotherapy: Understanding the significance of 230MeV
AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury (UK) has been completed and demonstrated to generate a full-energy proton beam (230MeV) required to treat deep-seated tumours. AVO is now liaising with its clinical partner, University Hospitals Birmingham (UHB) NHS Foundation Trust, to prepare for first-patient treatments in 2H’23. Following this significant project de-risking, our updated LIGHT model shows that AVO could become EBITDA-positive in 2025.
Please click on the link below for the full report: https://hardmanandco.com/research/corporate-research/understanding-the-significance-of-230mev/ If you are interested in meeting the company, you can register your interest by clicking on the above link
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
1537221 17-Jan-2023